WO2001079525A3 - Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same - Google Patents

Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same Download PDF

Info

Publication number
WO2001079525A3
WO2001079525A3 PCT/US2001/012395 US0112395W WO0179525A3 WO 2001079525 A3 WO2001079525 A3 WO 2001079525A3 US 0112395 W US0112395 W US 0112395W WO 0179525 A3 WO0179525 A3 WO 0179525A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
nucleic acids
therapeutic
purified
polypeptides
Prior art date
Application number
PCT/US2001/012395
Other languages
French (fr)
Other versions
WO2001079525A2 (en
Inventor
David B Mount
Eric Delpire
Gerardo Gamba
Alfred L George Jr
Original Assignee
Univ Vanderbilt
David B Mount
Eric Delpire
Gerardo Gamba
Alfred L George Jr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt, David B Mount, Eric Delpire, Gerardo Gamba, Alfred L George Jr filed Critical Univ Vanderbilt
Priority to JP2001577508A priority Critical patent/JP2005522179A/en
Priority to AU5542101A priority patent/AU5542101A/en
Priority to EP01928579A priority patent/EP1276893A4/en
Priority to CA002403547A priority patent/CA2403547A1/en
Priority to AU2001255421A priority patent/AU2001255421B2/en
Publication of WO2001079525A2 publication Critical patent/WO2001079525A2/en
Publication of WO2001079525A3 publication Critical patent/WO2001079525A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)

Abstract

KCC2, KCC3 and KCC4 potassium-chloride cotransporter proteins, and nucleic acid molecules encoding the same. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed, along with methods of producing each. Isolated and purified antibodies to KCC2, KCC3 and KCC4 homologs, and methods of producing the same, are also disclosed. KCC2, KCC3 and KCC4 gene products have biological activity in potassium-chloride cotransport. Thus, therapeutic methods involving this activity are also disclosed.
PCT/US2001/012395 2000-04-14 2001-04-16 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same WO2001079525A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2001577508A JP2005522179A (en) 2000-04-14 2001-04-16 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using them
AU5542101A AU5542101A (en) 2000-04-14 2001-04-16 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
EP01928579A EP1276893A4 (en) 2000-04-14 2001-04-16 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
CA002403547A CA2403547A1 (en) 2000-04-14 2001-04-16 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
AU2001255421A AU2001255421B2 (en) 2000-04-14 2001-04-16 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19735000P 2000-04-14 2000-04-14
US60/197,350 2000-04-14

Publications (2)

Publication Number Publication Date
WO2001079525A2 WO2001079525A2 (en) 2001-10-25
WO2001079525A3 true WO2001079525A3 (en) 2005-05-12

Family

ID=22729043

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/012395 WO2001079525A2 (en) 2000-04-14 2001-04-16 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same

Country Status (6)

Country Link
US (2) US7183075B2 (en)
EP (1) EP1276893A4 (en)
JP (1) JP2005522179A (en)
AU (2) AU5542101A (en)
CA (1) CA2403547A1 (en)
WO (1) WO2001079525A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1624936T3 (en) 2003-05-16 2010-03-15 Univ Laval CNS chloride modulation and applications thereof
JP2006223162A (en) * 2005-02-16 2006-08-31 Kitasato Gakuen Method for isolating and distinguishing renal macula densa cell, method for forming immortalized renal macula densa cell, cell strain thereof and transformed animal
WO2007056510A2 (en) * 2005-11-09 2007-05-18 The Children's Hospital Of Philadelphia Chloride transport upregulation for the treatment of traumatic brain injury
US20230033299A1 (en) * 2019-07-30 2023-02-02 NxGen Medicine Inc. Methods of Treating Pain Conditions and Compositions Related Thereto

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895807A (en) 1986-12-31 1990-01-23 Cherksey Bruce D Membrane channel protein and related therapeutic compounds
FR2659080B1 (en) 1990-03-02 1994-07-08 Adir NOVEL PYRIDYLSULFONYLUREA AND PYRIDYLSULFONYLTHIOURAE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5166162A (en) 1990-03-02 1992-11-24 Adir Et Compagnie Pyridylsulfonylurea and pyridylsulfonylthiourea compounds
US5410031A (en) 1992-02-24 1995-04-25 The Regents Of The University Of California Office Of Technology Transfer Nucleoside cotransporter protein cDNA
EP0560232A1 (en) 1992-03-09 1993-09-15 Hoechst Aktiengesellschaft Novel 7-aminolabdanes, a process for their preparation and their use as pharmaceutical agents
US5441875A (en) 1993-07-23 1995-08-15 Brigham And Women's Hospital Urea transporter polypeptide
WO1995020579A1 (en) 1994-01-28 1995-08-03 Pharmacia & Upjohn Company Cyanoguanidines as k-channel blockers
US5585401A (en) 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US5686266A (en) 1995-04-27 1997-11-11 Eli Lilly And Company Human brain sodium dependent inorganic phosphate cotransproter and related nucleic acid compounds
NZ329200A (en) 1996-12-16 1999-05-28 Hoechst Ag Sulphonamide substituted quinazoline, isoquinoline, quinoline or benzo[1,3-]oxazine derivatives and medicaments
JP2001508291A (en) 1996-12-31 2001-06-26 イェール ユニバーシティ Methods for diagnosis and treatment of pathological conditions caused by insufficient ion transport
US5985604A (en) 1997-02-24 1999-11-16 Incyte Pharmaceuticals, Inc. Human sodium-dependent phosphate cotransporter
WO1998053067A1 (en) 1997-05-20 1998-11-26 Yale University Nbc, a gene that encodes a member of the bicarbonate transporter family of proteins
WO2001057188A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001053312A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLOMQVIST, S.R. ET AL: "Distal Renal Tubular Acidosis in Mice that Lack the Forkhead Transcription Factor Foxil", J. CLIN. INVEST., vol. 113, no. 11, June 2004 (2004-06-01), pages 1560 - 1570, XP002978229 *
See also references of EP1276893A4 *
SHEN, M. ET AL: "The KCI Cotransporter Isoform KCC3 Can Play an Important Role in Cell Growth Regulation", PROC. NATL. ACAD. SCI., vol. 98, no. 25, 4 December 2001 (2001-12-04), pages 14714 - 14719, XP002978228 *

Also Published As

Publication number Publication date
EP1276893A1 (en) 2003-01-22
EP1276893A4 (en) 2005-05-04
AU5542101A (en) 2001-10-30
AU2001255421B2 (en) 2007-08-23
CA2403547A1 (en) 2001-10-25
JP2005522179A (en) 2005-07-28
US20030027983A1 (en) 2003-02-06
US20070207140A1 (en) 2007-09-06
WO2001079525A2 (en) 2001-10-25
US7183075B2 (en) 2007-02-27

Similar Documents

Publication Publication Date Title
WO1998031818A3 (en) Tace-like and matrilysin-like polypeptides
WO2002029083A3 (en) Industrial-scale serum-free production of recombinant proteins in mammalian cells
PL393644A1 (en) Host cell, method for producing a polypeptide in a host cell, antibody, antibody fragment, protein fusion, a pharmaceutical composition and method for treating cancer
BG100771A (en) Hematopoeic protein and ways and methods for its preparation
HK1082761A1 (en) Circular dna molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
EP2277889A3 (en) Fusion proteins of albumin and interferon beta
BRPI9811940A (en) expression vector for an interleukin-18 binding polypeptide (il-18-bp), prokaryotic host cell transformed with said vector, process for producing il-18-bp, fusion protein comprising said polypeptide, as well as il -18bp modified.
WO2006042158A3 (en) Methods and compositions for improving recombinant protein production
WO2001018172A3 (en) Fibroblast growth factor-like polypeptides
WO2001012659A3 (en) Human dna sequences
EE200000152A (en) Amino-terminally truncated forms of MCP-2, DNA molecules, expression vector, host cell, recombinant protein production method, use of protein and pharmaceutical composition
WO2002002783A3 (en) Expression vectors
PT95923A (en) PROCESS FOR THE PREPARATION OF PROTEIN COMPLEXES PROVIDING ACTIVITY OF FACTOR VIII.C
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
EE200000355A (en) IFN / IFNAR complex and corresponding molecule and their use, DNA, host cell, fusion protein production method, IFN type I prolongation method, pharmaceutical composition and use of IFNAR
WO2004005475A3 (en) Purified and isolated heparan sulfate 3-o-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same
WO2003008449A8 (en) Ntb-a, a surface molecule involved in natural killer cells activity
WO2001079525A3 (en) Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
CA2032167A1 (en) Dna coding for protein binds to enhancer of.alpha.-fetoprotein gene
DE60139113D1 (en) 18477, A HUMAN PROTEIN KINASE AND ITS USE
WO1998027932A3 (en) Cerebellum and embryo specific protein
WO2002063000A3 (en) Purified and isolated platelet calcium channel nucleic acids and polypeptides and therapeutic and screening methods using same
WO2002090500A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
WO2002014369A3 (en) Human kininogen d5 domain polypeptides and their use
WO1998029438A3 (en) Cortistatin polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001255421

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2403547

Country of ref document: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 577508

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001928579

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001928579

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)